Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Classification of positive inotropic agents

A M Feldman1

  • 1Peter Belfer Cardiac Laboratories, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Journal of the American College of Cardiology
|October 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to "clarification of enrolled subjects in tolvaptan HF trials".

Clinical pharmacology and therapeutics·2014
Same author

Vasopressin antagonists for patients with acute heart failure: interpreting new clinical and translational data.

Clinical pharmacology and therapeutics·2013
Same author

Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts.

Gene therapy·2007
Same author

Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy.

Clinical pharmacology and therapeutics·2007
Same author

Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences.

Clinical pharmacology and therapeutics·2007
Same author

Heart Failure Society of America: heart failure awareness.

Congestive heart failure (Greenwich, Conn.)·2002

A new classification system for inotropic agents categorizes drugs by their mechanism of action, aiding understanding of their benefits and limitations. This framework helps differentiate inotropic agents beyond generic views.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Inotropic agents are often viewed generically despite mechanistic differences.
  • A lack of a standardized classification system hinders nuanced understanding.
  • Existing antiarrhythmic classification systems offer a precedent.

Purpose of the Study:

  • To propose a novel classification system for inotropic agents.
  • To categorize agents based on their specific mechanisms of action.
  • To provide a framework for better understanding inotropic drug properties.

Main Methods:

  • Classification based on mechanisms of action.
  • Categorization into four classes: Class I (cAMP-mediated), Class II (ion channel/pump modulation), Class III (calcium regulation), and Class IV (multiple pathways).

Related Experiment Videos

Main Results:

  • Proposed a four-class system for inotropic agents based on distinct mechanisms.
  • Class I: Increased intracellular cyclic adenosine monophosphate.
  • Class II: Affecting ion channels or pumps.
  • Class III: Modulating intracellular calcium regulation.
  • Class IV: Augmenting contractility via multiple pathways.

Conclusions:

  • The proposed classification offers a framework for understanding inotropic agents.
  • It aids in differentiating traditional and investigational drugs.
  • This system highlights potential benefits and limitations based on mechanism.